Substituted dihydroisoindolones as allosteric modulators of glucokinase

A compound of Formula (I)

• wherein
• R1 is H or C1-6alkyl, wherein the C1-6 alkyl is optionally substituted with aryl,
• wherein said aryl is optionally substituted with C1-6alkyl, C2-6alkenyl, C2-6alkynyl, halo, nitro, hydroxyl, ethynyl, —CN, aryl, —SO3H, —C(O)OH, —C(O)NR′R″, —SR′, —OR′, —C(O)R′, —N(R′)(R″), —S(O)2—R′, and —S(O)2—N(R′)(R″), wherein R′ and R″ are independently selected from H, C1-6-alkyl, and aryl;
• R2 is 0-3 members independently selected from halo, —OR4, —SR4, —S(O)2—R4, carboxy, nitro, hydroxyl, amido, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, and amino optionally substituted with C1-6alkyl, aryl, wherein R4 is selected from H, C1-6alkyl, and aryl;
• wherein said C1-6alkyl is optionally substituted with one to three groups selected from oxo, amino, alkoxy, carboxy, nitro, hydroxyl, and halo;
• wherein said C2-6alkenyl is optionally substituted with one to three groups selected from amino, alkoxy, carboxy, nitro, hydroxyl, and halo;
• wherein said C2-6alkynyl is optionally substituted with one to three groups selected from amino, alkoxy, carboxy, nitro, hydroxyl, and halo;
• wherein said aryl is optionally substituted with C1-6alkyl, C2-6alkenyl, C2-6alkynyl, halo, nitro, hydroxyl, ethynyl, —CN, aryl, —SO3H, —C(O)OH, —C(O)O—C1-4alkyl, —C(O)NR′R″, —SR′, —OR′, —C(O)R′, —N(R′)(R″), —S(O)2—R′, and —S(O)2—N(R′)(R″), wherein R′ and R″ are independently selected from H, C1-6-alkyl, and aryl;
• A is phenyl;
• B is pyridine, said pyridine being connected to N(1) through a ring carbon atom adjacent to a ring nitrogen, and said pyridine being further optionally substituted with 1 or 2 members selected from C1-4alkyl, C2-4alkenyl, halo, —CN, aryl, —SO3H, —C(O)OH, —C(O)O—C1-4alkyl, —OR4, —SR4, —C(O)R4, —N(R4)(R5), —C(O)—N(R4)(R5), —S(O)2—R4, and —S(O)2—N(R4)(R5), wherein R4 and R5 are independently selected from H, C1-6alkyl, and aryl;
• wherein said C1-6alkyl is optionally substituted with one to three groups selected from oxo, amino, alkoxy, carboxy, nitro, hydroxyl, and halo;
• wherein said C2-4alkenyl is optionally substituted with one to three groups selected from amino, alkoxy, carboxy, nitro, hydroxyl, and halo;
• wherein said aryl is optionally substituted with C1-6alkyl, C2-6alkenyl, C2-6alkynyl, halo, nitro, hydroxyl, ethynyl, —CN, aryl, —SO3H, —C(O)OH, —C(O)O—C1-4alkyl, —C(O)NR′R″, —SR′, —OR′, —C(O)R′, —N(R′)(R″), —S(O)2—R′, and —S(O)2—N(R′)(R″), wherein R′ and R″ are independently selected from H, C1-6-alkyl, and aryl;
• X is C1-3alkylene, wherein said C1-3alkylene is optionally substituted with one or two groups selected from halo;
• and
• Y is —C(O)—, wherein said C(O) functionality is adjacent to N(1);
• or an optical isomer, enantiomer, diastereomer, racemate or pharmaceutically acceptable salt thereof.